Hypoxic Preconditioning Increases Survival and Pro-Angiogenic Capacity of Human Cord Blood Mesenchymal Stromal Cells In Vitro

Hypoxic preconditioning was shown to improve the therapeutic efficacy of bone marrow-derived multipotent mesenchymal stromal cells (MSCs) upon transplantation in ischemic tissue. Given the interest in clinical applications of umbilical cord blood-derived MSCs, we developed a specific hypoxic preconditioning protocol and investigated its anti-apoptotic and pro-angiogenic effects on cord blood MSCs undergoing simulated ischemia in vitro by subjecting them to hypoxia and nutrient deprivation with or without preceding hypoxic preconditioning. Cell number, metabolic activity, surface marker expression, chromosomal stability, apoptosis (caspases-3/7 activity) and necrosis were determined, and phosphorylation, mRNA expression and protein secretion of selected apoptosis and angiogenesis-regulating factors were quantified. Then, human umbilical vein endothelial cells (HUVEC) were subjected to simulated ischemia in co-culture with hypoxically preconditioned or naïve cord blood MSCs, and HUVEC proliferation was measured. Migration, proliferation and nitric oxide production of HUVECs were determined in presence of cord blood MSC-conditioned medium. Cord blood MSCs proved least sensitive to simulated ischemia when they were preconditioned for 24 h, while their basic behavior, immunophenotype and karyotype in culture remained unchanged. Here, “post-ischemic” cell number and metabolic activity were enhanced and caspase-3/7 activity and lactate dehydrogenase release were reduced as compared to non-preconditioned cells. Phosphorylation of AKT and BAD, mRNA expression of BCL-XL, BAG1 and VEGF, and VEGF protein secretion were higher in preconditioned cells. Hypoxically preconditioned cord blood MSCs enhanced HUVEC proliferation and migration, while nitric oxide production remained unchanged. We conclude that hypoxic preconditioning protects cord blood MSCs by activation of anti-apoptotic signaling mechanisms and enhances their angiogenic potential. Hence, hypoxic preconditioning might be a translationally relevant strategy to increase the tolerance of cord blood MSCs to ischemia and improve their therapeutic efficacy in clinical applications.

[1]  M. Wood,et al.  Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles. , 2015, Human gene therapy.

[2]  J. Nolta,et al.  Hypoxic Preconditioning of Mesenchymal Stromal Cells Induces Metabolic Changes, Enhances Survival, and Promotes Cell Retention In Vivo , 2015, Stem cells.

[3]  K. Hoffmann,et al.  Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. , 2015, Cytotherapy.

[4]  S. Koh,et al.  Hypoxia/Reoxygenation-Preconditioned Human Bone Marrow-Derived Mesenchymal Stromal Cells Rescue Ischemic Rat Cortical Neurons by Enhancing Trophic Factor Release , 2015, Molecular Neurobiology.

[5]  K. Webster,et al.  Leptin Signaling Is Required for Augmented Therapeutic Properties of Mesenchymal Stem Cells Conferred by Hypoxia Preconditioning , 2014, Stem cells.

[6]  Xinyang Hu,et al.  Hypoxia Preconditioned Mesenchymal Stem Cells Prevent Cardiac Fibroblast Activation and Collagen Production via Leptin , 2014, PloS one.

[7]  C. Stamm,et al.  Cord Blood Mesenchymal Stromal Cell-Conditioned Medium Protects Endothelial Cells via STAT3 Signaling , 2014, Cellular Physiology and Biochemistry.

[8]  T. Ma,et al.  Preconditioning Stem Cells for In Vivo Delivery , 2014, BioResearch open access.

[9]  Yonghong Yang,et al.  Hypoxia-Pretreated Human MSCs Attenuate Acute Kidney Injury through Enhanced Angiogenic and Antioxidative Capacities , 2014, BioMed research international.

[10]  C. Stamm,et al.  Mechanisms of paracrine cardioprotection by cord blood mesenchymal stromal cells. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  J. Ge,et al.  Inducible Metabolic Adaptation Promotes Mesenchymal Stem Cell Therapy for Ischemia: A Hypoxia-Induced and Glycogen-Based Energy Prestorage Strategy , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[12]  S. Hung,et al.  Hypoxic mesenchymal stem cells engraft and ameliorate limb ischaemia in allogeneic recipients. , 2014, Cardiovascular research.

[13]  Xinyang Hu,et al.  Increased leptin by hypoxic-preconditioning promotes autophagy of mesenchymal stem cells and protects them from apoptosis , 2014, Science China Life Sciences.

[14]  Darcy L. DiFede,et al.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. , 2014, JAMA.

[15]  C. Stamm,et al.  Impact of heart failure on the behavior of human neonatal stem cells in vitro , 2013, Journal of Translational Medicine.

[16]  Mohammad Tariqur Rahman,et al.  Hypoxic Culture Conditions as a Solution for Mesenchymal Stem Cell Based Regenerative Therapy , 2013, TheScientificWorldJournal.

[17]  A. Das,et al.  A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia , 2013, Journal of Translational Medicine.

[18]  K. Kang,et al.  A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease. , 2013, International journal of stem cells.

[19]  T. Couffinhal,et al.  Hypoxia-preconditioned mesenchymal stromal cells improve cardiac function in a swine model of chronic myocardial ischaemia. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  M. Simionescu,et al.  Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. , 2013, Stem cells and development.

[21]  A. Galinier,et al.  Aging-related Decrease of Human ASC Angiogenic Potential Is Reversed by Hypoxia Preconditioning Through ROS Production. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[23]  Ha Won Kim,et al.  Concomitant activation of miR-107/PDCD10 and hypoxamir-210/Casp8ap2 and their role in cytoprotection during ischemic preconditioning of stem cells. , 2012, Antioxidants & redox signaling.

[24]  Ling Wei,et al.  Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats , 2012, Neurobiology of Disease.

[25]  M. Ashraf,et al.  Stem cell-based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of infarcted heart function , 2012, Journal of Molecular Medicine.

[26]  W. Xue,et al.  The Role of SDF-1-CXCR4/CXCR7 Axis in the Therapeutic Effects of Hypoxia-Preconditioned Mesenchymal Stem Cells for Renal Ischemia/Reperfusion Injury , 2012, PloS one.

[27]  Ling Wei,et al.  Hypoxic preconditioning enhances bone marrow mesenchymal stem cell migration via Kv2.1 channel and FAK activation. , 2011, American Journal of Physiology - Cell Physiology.

[28]  Nan Ma,et al.  Cell Origin of Human Mesenchymal Stem Cells Determines a Different Healing Performance in Cardiac Regeneration , 2011, PloS one.

[29]  Amir Lerman,et al.  Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. , 2011, Life sciences.

[30]  Periannan Kuppusamy,et al.  Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. , 2010, American journal of physiology. Cell physiology.

[31]  Manuel T. Silva.  Secondary necrosis: The natural outcome of the complete apoptotic program , 2010, FEBS letters.

[32]  W. Xue,et al.  Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. , 2010, Biochemical and biophysical research communications.

[33]  T. Couffinhal,et al.  Hypoxia Preconditioned Mesenchymal Stem Cells Improve Vascular and Skeletal Muscle Fiber Regeneration After Ischemia Through a Wnt4-dependent Pathway. , 2010, Molecular Therapy.

[34]  Shujia Jiang,et al.  Ischemic Preconditioning Augments Survival of Stem Cells via miR-210 Expression by Targeting Caspase-8-associated Protein 2* , 2009, The Journal of Biological Chemistry.

[35]  B. Trimarco,et al.  Cross-Talk Between PKA and Akt Protects Endothelial Cells From Apoptosis in the Late Ischemic Preconditioning , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[36]  Yong Sun,et al.  The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. , 2009, The Canadian journal of cardiology.

[37]  Jun Jiang,et al.  Anoxic preconditioning: a way to enhance the cardioprotection of mesenchymal stem cells. , 2009, International journal of cardiology.

[38]  D. Link,et al.  Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem Cells , 2008, Stem cells.

[39]  Ling Wei,et al.  Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. , 2008, The Journal of thoracic and cardiovascular surgery.

[40]  Jun Jiang,et al.  Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells , 2008, Acta Pharmacologica Sinica.

[41]  Hong Chen,et al.  Delayed cytoprotection induced by hypoxic preconditioning in cultured neonatal rat cardiomyocytes: role of GRP78. , 2007, Life sciences.

[42]  Nan Ma,et al.  Bcl‐2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function , 2007, Stem cells.

[43]  M. Ashraf,et al.  Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine Signaling , 2006, Circulation research.

[44]  Hoon Han,et al.  Successful Stem Cell Therapy Using Umbilical Cord Blood‐Derived Multipotent Stem Cells for Buerger's Disease and Ischemic Limb Disease Animal Model , 2006, Stem cells.

[45]  Hermann Eichler,et al.  Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue , 2006, Stem cells.

[46]  Young Jin Kim,et al.  Isolation of Mesenchymal Stem Cells from Cryopreserved Human Umbilical Cord Blood , 2005, International journal of hematology.

[47]  Myoung-Woo Lee,et al.  Mesenchymal stem cells from cryopreserved human umbilical cord blood. , 2004, Biochemical and biophysical research communications.

[48]  N. Maulik,et al.  Role of Akt Signaling in Mitochondrial Survival Pathway Triggered by Hypoxic Preconditioning , 2004, Circulation.